Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURANCE-2
2015-002348-14Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic hepatitis C (CHC) comparing ABT-493 + ABT-530 with Placebo (2 arms). Primary endpoints: SVR12 and Safety. Started Sep 2015; status: completed.
02
Drugs
glecaprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-002348-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002348-14.